Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bruce Acres

Showing results (21-30 of 30) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 30 results.
Blood|May 27, 2004
Adenovirus-mediated intralesional interferon-gamma gene transfer induces tumor regressions in cutaneous lymphomasReinhard Dummer, Jessica C Hassel, Friederike Fellenberg, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|April 13, 2004
Phase I trial of antigen-specific gene therapy using a recombinant vaccinia virus encoding MUC-1 and IL-2 in MUC-1-positive patients with advanced prostate cancerAllan J Pantuck, Arndt van Ophoven, Barbara J Gitlitz, et al.
Cancer Gene Therapy|April 19, 2002
Tumor gene therapy by MVA-mediated expression of T-cell-stimulating antibodiesStephane Paul, Etienne Regulier, Ronald Rooke, et al.
Cancer Gene Therapy|March 16, 2002
Immunotherapy of metastatic melanoma by intratumoral injections of Vero cells producing human IL-2: phase II randomized study comparing two dose levelsChristoph Rochlitz, Brigitte Dreno, Peter Jantscheff, et al.
Journal of Biomedicine & Biotechnology|September 17, 2003
Metastatic Breast Tumour Regression Following Treatment by a Gene-Modified Vaccinia Virus Expressing MUC1 and IL-2Susy Scholl, Patrick Squiban, Nadine Bizouarne, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 3, 2008
A phase II study of Tg4010 (Mva-Muc1-Il2) in association with chemotherapy in patients with stage III/IV Non-small cell lung cancerRodryg Ramlau, Elisabeth Quoix, Janusz Rolski, et al.
Cancer Immunology, Immunotherapy : CII|November 12, 2010
A phase II study of the cancer vaccine TG4010 alone and in combination with cytokines in patients with metastatic renal clear-cell carcinoma: clinical and immunological findingsStéphane Oudard, Olivier Rixe, Benoit Beuselinck, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|April 8, 2010
Phase II clinical trial of intratumoral application of TG1042 (adenovirus-interferon-gamma) in patients with advanced cutaneous T-cell lymphomas and multilesional cutaneous B-cell lymphomasReinhard Dummer, Stefan Eichmüller, Sylke Gellrich, et al.
Plos One|March 4, 2014
TG1042 (Adenovirus-interferon-γ) in primary cutaneous B-cell lymphomas: a phase II clinical trialBrigitte Dreno, Mirjana Urosevic-Maiwald, Youn Kim, et al.
The Lancet. Oncology|October 25, 2011
Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer: a controlled phase 2B trialElisabeth Quoix, Rodryg Ramlau, Virginie Westeel, et al.
Pageof 3

Showing results (21-30 of 30) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 30 results.
Blood|May 27, 2004
Adenovirus-mediated intralesional interferon-gamma gene transfer induces tumor regressions in cutaneous lymphomasReinhard Dummer, Jessica C Hassel, Friederike Fellenberg, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|April 13, 2004
Phase I trial of antigen-specific gene therapy using a recombinant vaccinia virus encoding MUC-1 and IL-2 in MUC-1-positive patients with advanced prostate cancerAllan J Pantuck, Arndt van Ophoven, Barbara J Gitlitz, et al.
Cancer Gene Therapy|April 19, 2002
Tumor gene therapy by MVA-mediated expression of T-cell-stimulating antibodiesStephane Paul, Etienne Regulier, Ronald Rooke, et al.
Cancer Gene Therapy|March 16, 2002
Immunotherapy of metastatic melanoma by intratumoral injections of Vero cells producing human IL-2: phase II randomized study comparing two dose levelsChristoph Rochlitz, Brigitte Dreno, Peter Jantscheff, et al.
Journal of Biomedicine & Biotechnology|September 17, 2003
Metastatic Breast Tumour Regression Following Treatment by a Gene-Modified Vaccinia Virus Expressing MUC1 and IL-2Susy Scholl, Patrick Squiban, Nadine Bizouarne, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 3, 2008
A phase II study of Tg4010 (Mva-Muc1-Il2) in association with chemotherapy in patients with stage III/IV Non-small cell lung cancerRodryg Ramlau, Elisabeth Quoix, Janusz Rolski, et al.
Cancer Immunology, Immunotherapy : CII|November 12, 2010
A phase II study of the cancer vaccine TG4010 alone and in combination with cytokines in patients with metastatic renal clear-cell carcinoma: clinical and immunological findingsStéphane Oudard, Olivier Rixe, Benoit Beuselinck, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|April 8, 2010
Phase II clinical trial of intratumoral application of TG1042 (adenovirus-interferon-gamma) in patients with advanced cutaneous T-cell lymphomas and multilesional cutaneous B-cell lymphomasReinhard Dummer, Stefan Eichmüller, Sylke Gellrich, et al.
Plos One|March 4, 2014
TG1042 (Adenovirus-interferon-γ) in primary cutaneous B-cell lymphomas: a phase II clinical trialBrigitte Dreno, Mirjana Urosevic-Maiwald, Youn Kim, et al.
The Lancet. Oncology|October 25, 2011
Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer: a controlled phase 2B trialElisabeth Quoix, Rodryg Ramlau, Virginie Westeel, et al.
Pageof 3